These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15719120)

  • 1. Saccharin as a salt former. Enhanced solubilities of saccharinates of active pharmaceutical ingredients.
    Bhatt PM; Ravindra NV; Banerjee R; Desiraju GR
    Chem Commun (Camb); 2005 Feb; (8):1073-5. PubMed ID: 15719120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities.
    Cavanagh KL; Maheshwari C; Rodríguez-Hornedo N
    J Pharm Sci; 2018 Jan; 107(1):113-120. PubMed ID: 29097226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation into the influence of counterion on the properties of some amorphous organic salts.
    Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
    Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.
    David SE; Timmins P; Conway BR
    Drug Dev Ind Pharm; 2012 Jan; 38(1):93-103. PubMed ID: 22118222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallization of a salt of a weak organic acid and base: solubility relations, supersaturation control and polymorphic behavior.
    Jones HP; Davey RJ; Cox BG
    J Phys Chem B; 2005 Mar; 109(11):5273-8. PubMed ID: 16863194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the solubility and solid-state properties of saccharin salts of fluoroquinolones.
    Romañuk CB; Manzo RH; Linck YG; Chattah AK; Monti GA; Olivera ME
    J Pharm Sci; 2009 Oct; 98(10):3788-801. PubMed ID: 19226631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid-state architecture of saccharin salts of some diamines.
    Banerjee R; Saha BK; Desiraju GR
    Acta Crystallogr C; 2006 Jun; 62(Pt 6):o346-9. PubMed ID: 16763324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms by which moisture generates cocrystals.
    Jayasankar A; Good DJ; Rodríguez-Hornedo N
    Mol Pharm; 2007; 4(3):360-72. PubMed ID: 17488034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of salt screening methodologies.
    Fernández Casares A; Nap WM; Ten Figás G; Huizenga P; Groot R; Hoffmann M
    J Pharm Pharmacol; 2015 Jun; 67(6):812-22. PubMed ID: 25683791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid-state structure and temperature/evacuation-induced dehydration of sodium saccharinate 1.875 hydrate.
    Naumov P; Jovanovski G; Grupce O; Kaitner B; Rae AD; Ng SW
    Angew Chem Int Ed Engl; 2005 Feb; 44(8):1251-4. PubMed ID: 15635710
    [No Abstract]   [Full Text] [Related]  

  • 12. pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media.
    Alhalaweh A; Roy L; Rodríguez-Hornedo N; Velaga SP
    Mol Pharm; 2012 Sep; 9(9):2605-12. PubMed ID: 22867056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of aqueous content in small scale salt screening--improving hit rate for weakly basic, low solubility drugs.
    Tarsa PB; Towler CS; Woollam G; Berghausen J
    Eur J Pharm Sci; 2010 Sep; 41(1):23-30. PubMed ID: 20553863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural studies of the system Na(saccharinate)n H2O: a model for crystallization.
    Banerjee R; Bhatt PM; Kirchner MT; Desiraju GR
    Angew Chem Int Ed Engl; 2005 Apr; 44(17):2515-20. PubMed ID: 15786521
    [No Abstract]   [Full Text] [Related]  

  • 15. Crystalline vs. ionic liquid salt forms of active pharmaceutical ingredients: a position paper.
    Stoimenovski J; MacFarlane DR; Bica K; Rogers RD
    Pharm Res; 2010 Apr; 27(4):521-6. PubMed ID: 20143257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular structures of 3-[(2,2,3,3-tetrafluoropropoxy)methyl]- and 3-[(2,2,3,3,3-pentafluoropropoxy)methyl]pyridinium saccharinates.
    Lu N; Chiang HF; Wei RJ; Wen YS; Liu LK
    Acta Crystallogr C Struct Chem; 2017 Aug; 73(Pt 8):593-599. PubMed ID: 28776509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting crystallization of hydrates.
    Tian F; Qu H; Zimmermann A; Munk T; Jørgensen AC; Rantanen J
    J Pharm Pharmacol; 2010 Nov; 62(11):1534-46. PubMed ID: 21039539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
    Paulekuhn GS; Dressman JB; Saal C
    J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
    Elder DP; Holm R; Diego HL
    Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures and physicochemical properties of vortioxetine salts.
    Zhou X; Hu X; Wu S; Ye J; Sun M; Gu J; Zhu J; Zhang Z
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2016 Oct; 72(Pt 5):723-732. PubMed ID: 27698313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.